Amphastar Pharmaceuticals, Inc. (AMPH) News

Amphastar Pharmaceuticals, Inc. (AMPH): $27.56

-0.03 (-0.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter AMPH News Items

AMPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AMPH News Highlights

  • AMPH's 30 day story count now stands at 3.
  • Over the past 14 days, the trend for AMPH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about AMPH are SR.

Latest AMPH News From Around the Web

Below are the latest news stories about AMPHASTAR PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMPH as an investment opportunity.

7 Safe Stocks to Rely on When the Market Swerves

Nevertheless, the discouraging prospect of more pain ahead doesn't mean you need to sit in cash.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | September 19, 2022

Top Pharmaceutical Stocks for Q4 2022

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2022.

Yahoo | September 16, 2022

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Yahoo | September 5, 2022

Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jacob Liawatidewi, Executive V.P. of Corporate Administration Center and Sales and Marketing and Tony Marrs Sr. Vice President of Regulatory Affairs and Clinical Operations, will participate in an Analyst-Moderated fireside chat at the Wells Fargo 2022 Healthcare Conference on September 7th, 2022 at 1:20 pm Eastern Standard Time.

Yahoo | September 2, 2022

Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's New Drug Application ("NDA") for Epinephrine injection USP, 1 mg/10mL (0.1 mg/mL) Single Dose Pre-Filled Syringe. Epinephrine injection is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

Yahoo | August 16, 2022

Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)

E ratio of 23.46.Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock.

Howard Kim on TipRanks | August 9, 2022

Why No. 1 Biotech Amphastar Crashed As Runaway Syndax Hit A Profit-Taking Zone

Top-ranked biotech stock Amphastar crashed Tuesday after the company received its second Food and Drug Administration rejection since June.

Yahoo | August 9, 2022

Amphastar Pharmaceuticals (AMPH) Q2 2022 Earnings Call Transcript

Image source: The Motley Fool. Amphastar Pharmaceuticals (NASDAQ: AMPH)Q2 2022 Earnings CallAug 08, 2022, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the Amphastar Pharmaceuticals second-quarter earnings call.

Yahoo | August 9, 2022

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 5.41% and 4.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 8, 2022

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2022.

Yahoo | August 8, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5289 seconds.